Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. We have met the preestablished endpoint for our Phase 2 clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Employing our proprietary selection technology and discovery and development platform (CHOICE), we have developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. These provide potential utility in multiple tumor types in both the monotherapy and combination therapy settings, via physician- preferred administration techniques, including regional (e.g., intraperitoneal), local and systemic (e.g., intravenous) delivery routes. Informed by our CHOICE platform and supported by extensive clinical and preclinical data, we believe we have the capacity to develop a pipeline of treatment options to address high unmet medical needs for those patients with insignificant or unsatisfactory responses to standard- of-care therapies, including chemotherapies. From this library, we selected Olvi-Vec, which we believe has the potential to exhibit anti-tumor properties, including potent oncolytic properties (tumor cell lysis), and to activate both the innate and adaptive arms of the immune system, to produce favorable changes within the tumor microenvironment. The personalized and multi-modal immune activation generated by Olvi-Vec is designed with the goal to yield clinically-meaningful anti-tumor responses to virus treatment alone and in combination with other existing treatment modalities. We believe Olvi-Vec currently represents the most advanced clinical development program throughout the oncolytic treatment landscape involving the non-local administration (i.e., non-intratumorally) of viral immunotherapies.
Company profile
Ticker
GNLX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GENELUX CORP
SEC CIK
GNLX stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
9 Apr 24
S-8
Registration of securities for employees
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
8 Feb 24
UPLOAD
Letter from SEC
8 Feb 24
8-K
Regulation FD Disclosure
5 Feb 24
8-K
Results of Operations and Financial Condition
2 Feb 24
S-3
Shelf registration
2 Feb 24
8-K
Regulation FD Disclosure
12 Dec 23
Latest ownership filings
4
Aladar Szalay
18 Apr 24
144/A
Notice of proposed sale of securities (amended)
15 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
SC 13G
Szalay Aladar
2 Feb 24
4
Yong Yu
18 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
4
James L Tyree
14 Dec 23
4
John Thomas
14 Dec 23
144
Notice of proposed sale of securities
13 Dec 23
144
Notice of proposed sale of securities
13 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 29.87 mm | 29.87 mm | 29.87 mm | 29.87 mm | 29.87 mm | 29.87 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.78 mm | 1.43 mm | (no burn) | 349.00 k |
Cash used (since last report) | n/a | n/a | 11.92 mm | 9.59 mm | n/a | 2.33 mm |
Cash remaining | n/a | n/a | 17.95 mm | 20.28 mm | n/a | 27.53 mm |
Runway (months of cash) | n/a | n/a | 10.1 | 14.1 | n/a | 78.9 |
Institutional ownership, Q3 2023
15.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 56 |
Opened positions | 25 |
Closed positions | 4 |
Increased positions | 26 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 102.96 bn |
Total shares | 4.24 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 1.20 mm | $29.29 bn |
Vanguard | 980.99 k | $24.02 bn |
Geode Capital Management | 386.63 k | $9.47 bn |
Provident Wealth Management | 335.26 k | $8.21 bn |
STT State Street | 231.07 k | $5.66 bn |
AE Wealth Management | 194.88 k | $4.77 bn |
NTRS Northern Trust | 160.82 k | $3.94 bn |
Charles Schwab Investment Management | 147.61 k | $3.61 bn |
BK Bank Of New York Mellon | 53.94 k | $1.32 bn |
AMG National Trust Bank | 50.35 k | $1.23 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Aladar Szalay | Common Stock | Sell | Dispose S | Yes | No | 3.7131 | 22,737 | 84.42 k | 1,300,125 |
16 Apr 24 | Aladar Szalay | Common Stock | Sell | Dispose S | Yes | No | 3.529 | 48,683 | 171.80 k | 1,322,862 |
15 Dec 23 | Tony Yu | Common Stock | Sell | Dispose S | No | No | 14.1763 | 5,803 | 82.27 k | 0 |
15 Dec 23 | Tony Yu | Common Stock | Sell | Dispose S | No | No | 12.9401 | 26,732 | 345.91 k | 5,803 |
13 Dec 23 | John Thomas | Common Stock | Sell | Dispose S | No | No | 13.9277 | 1,927 | 26.84 k | 463,460 |
13 Dec 23 | John Thomas | Common Stock | Sell | Dispose S | No | No | 13.2261 | 7,073 | 93.55 k | 465,387 |
13 Dec 23 | Tyree James L | Common Stock | Sell | Dispose S | No | No | 13.7327 | 3,347 | 45.96 k | 3,460 |
13 Dec 23 | Tyree James L | Common Stock | Sell | Dispose S | No | No | 12.9145 | 5,653 | 73.01 k | 6,807 |
7 Dec 23 | Tony Yu | Common Stock | Sell | Dispose S | No | No | 11.8477 | 36,800 | 436.00 k | 32,535 |
News
Benchmark Reiterates Speculative Buy on Genelux, Maintains $30 Price Target
3 Apr 24
HC Wainwright & Co. Maintains Buy on Genelux, Lowers Price Target to $32
2 Apr 24
Genelux Q4 EPS $(0.25) Misses $(0.19) Estimate, Cash Balance of $23.2M
1 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
8 Mar 24